A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line

BACKGROUND: Although chronic myeloid leukemia (CML) treatment has improved since the introduction of imatinib mesylate (IM), cases of resistance have been reported. This resistance has been associated with the emergence of multidrug resistance (MDR) phenotype, as a BCR-ABL independent mechanism. The...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Corrêa, Stephany, Pizzatti, Luciana, Du Rocher, Bárbara, Mencalha, André, Pinto, Daniela, Abdelhay, Eliana
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3361502/
https://ncbi.nlm.nih.gov/pubmed/22458888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-5956-10-23
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados